Regulatory

CLINUVEL
Posted by CLINUVEL
May 9, 2023

CLINUVEL escalates PRÉNUMBRA® to moderate/severe stroke patients

CLINUVEL announced the escalation of PRÉNUMBRA® Instant to moderate-to-severe and severe stroke...

Read More
CLINUVEL
Posted by CLINUVEL
May 1, 2023

Expansion of CLINUVEL’s global porphyria programs

CLINUVEL today released an update on the use its drug SCENESSE® (afamelanotide...

Read More
CLINUVEL
Posted by CLINUVEL
March 30, 2023

Investor Presentation - NYC Nasdaq Event

CLINUVEL hosted a Rendez-Vous evening event at the Nasdaq in New York...

Read More
CLINUVEL
Posted by CLINUVEL
March 20, 2023

First stroke patient treated with PRÉNUMBRA® Instant

CLINUVEL has started its second stroke trial (CUV803) with the first patient...

Read More
CLINUVEL
Posted by CLINUVEL
March 13, 2023

Statement on Silicon Valley Bank (SVB)

Melbourne, Australia, 13 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
Lachlan Hay
Posted by Lachlan Hay
March 10, 2023
Lachlan Hay
Posted by Lachlan Hay
March 9, 2023

Commercial Update SCENESSE®

CLINUVEL today published its 2022 status report on the commercial distribution of...

Read More
CLINUVEL
Posted by CLINUVEL
March 2, 2023

Relief from Quarterly Reporting

Melbourne, Australia, 2 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
February 28, 2023

Proposed issue of Securities

Melbourne, Australia, 28 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
February 24, 2023

Global SCENESSE® demand drives increased CLINUVEL revenues, earnings

Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
February 24, 2023

Appendix 4D Half Yearly Report

Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
February 2, 2023

Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population

Melbourne, Australia, 02 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
January 31, 2023

Appendix 4C & Activity Report

Melbourne, Australia, 31 January 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
January 27, 2023

Technical Note: Developing a melanocortin pipeline

CLINUVEL today announced an update on its commercial development of the analogue...

Read More
CLINUVEL
Posted by CLINUVEL
January 23, 2023

NEURACTHEL® manufacturing processes advance

CLINUVEL today announced an update on its commercial development of the analogue...

Read More